Skip to main content
SpringerLink
Log in

Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a guide to its use in the EU

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The quadrivalent human papillomavirus (HPV) [types 6, 11, 16, 18] recombinant vaccine (Gardasil®) is approved in the EU for use from the age of 9 years for the prevention of premalignant anogenital lesions and cervical and anal cancers, and genital warts caused by the vaccine HPV types. In clinical trials, quadrivalent HPV vaccine provided high-level protection against infection or disease caused by the vaccine HPV types in females aged 15–45 years who are negative for the vaccine types. Quadrivalent HPV vaccine also provided high-level protection against genital warts, anogenital precancerous lesions and persistent infection caused by the vaccine HPV types in males aged 16–26 years who are negative for the vaccine types in clinical trials. In addition, bridging studies show robust immune responses in young girls and boys aged from 9 years, allowing extrapolation of the efficacy results seen in clinical trials and approval of quadrivalent HPV vaccine for use from the age of 9 years. The prophylactic efficacy of HPV vaccination was also shown in real-world settings. Quadrivalent HPV vaccine is generally well tolerated. Thus, quadrivalent HPV vaccine offers an effective means, in combination with screening programmes, to substantially reduce the burden of cervical cancer. In addition, it is effective in reducing the burden of HPV-related anogenital disease, including anal cancers and genital warts, in females and males.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG Int J Obstet Gynaecol. 2002;109(1):96–8.

    Article  Google Scholar 

  2. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278–85.

    Article  CAS  PubMed  Google Scholar 

  3. GLOBOCAN. 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon: International Agency for Research on Cancer; 2014.

    Google Scholar 

  4. McCormack PL. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. Drugs. 2014;74(11):1253–83.

    Article  CAS  PubMed  Google Scholar 

  5. Gardasil (human papillomavirus vaccine [types 6, 11, 16, 18], recombinant, adsorbed): summary of product characteristics. London: European Medicines Agency; 2014.

  6. Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs. 2010;70(9):1079–98.

    Article  PubMed  Google Scholar 

  7. Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br J Cancer. 2007;96(9):1320–3.

    CAS  PubMed Central  PubMed  Google Scholar 

  8. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5):2135–45.

    Article  PubMed  Google Scholar 

  9. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–802.

    Article  CAS  PubMed  Google Scholar 

  10. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26(3):201–9.

    Article  PubMed  Google Scholar 

  11. Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659–64.

    Article  CAS  PubMed  Google Scholar 

  12. Jacobson DL, Bousvaros A, Ashworth L, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(7):1441–9.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Kahn JA, Xu J, Kapogiannis BG, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013;57(5):735–44.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202(8):1246–53.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010;55(2):197–204.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–43.

    Article  CAS  PubMed  Google Scholar 

  17. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27.

    Article  Google Scholar 

  18. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8.

    Article  PubMed  Google Scholar 

  19. Yoshikawa H, Ebihara K, Tanaka Y, et al. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci. 2013;104(4):465–72.

    Article  CAS  PubMed  Google Scholar 

  20. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949–57.

    Article  CAS  PubMed  Google Scholar 

  21. Castellsagué X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105(1):28–37.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009;2(10):868–78.

    Article  PubMed  Google Scholar 

  23. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693–702.

    Article  CAS  PubMed  Google Scholar 

  24. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459–66.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007;196(10):1438–46.

    Article  Google Scholar 

  26. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5(10):696–704.

    Article  CAS  PubMed  Google Scholar 

  27. Joura EA, Garland SM, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012;344:e1401.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol. 2013;130(2):264–8.

    Article  CAS  PubMed  Google Scholar 

  29. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85.

    Article  CAS  PubMed  Google Scholar 

  31. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199(7):926–35.

    Article  PubMed  Google Scholar 

  32. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis. 2009;199(7):936–44.

    Article  PubMed  Google Scholar 

  33. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208(3):385–93.

    Article  CAS  PubMed  Google Scholar 

  34. Delere Y, Remschmidt C, Leuschner J, et al. Human papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis. 2014;14(1):87.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.

    Article  PubMed  Google Scholar 

  36. Korostil IA, Ali H, Guy RJ, et al. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex Transm Dis. 2013;40(11):833–5.

    Article  PubMed  Google Scholar 

  37. Baandrup L, Blomberg M, Dehlendorff C, et al. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013;40(2):130–5.

    PubMed  Google Scholar 

  38. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085–92.

    Article  PubMed  Google Scholar 

  39. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11:227.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Baldur-Felskov B, Dehlendorff C, Munk C, et al. Early impact of human papillomavirus vaccination on cervical neoplasia: nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014; doi:10.1093/jnci/djt460.

    PubMed  Google Scholar 

  42. Niccolai LM, Julian PJ, Meek JI, et al. Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. Cancer Epidemiol Biomarkers Prev. 2013;22(8):1446–50.

    Article  PubMed  Google Scholar 

  43. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25(26):4931–9.

    Article  CAS  PubMed  Google Scholar 

  44. Nygard M, Kruger Kjaer S, Dillner J, et al. Long-term effectiveness and immunogenicitity of Gardasil in the Nordic countries (abstract no. OC 6-3). In: EUROGIN 2013: HPV at a crossroads—30 years of research and practice. Florence; 3–6 Nov 2013.

  45. Ferris D, Samakoses R, Block SL, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134(3):e657–65.

    Article  PubMed  Google Scholar 

  46. Bonanni P, Cohet C, Kjaer SK, et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine. 2010;28(30):4719–30.

    Article  PubMed  Google Scholar 

  47. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol. 2009;114(6):1179–88.

    Article  PubMed  Google Scholar 

  48. Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol. 2009;114(6):1170–8.

    Article  PubMed  Google Scholar 

  49. Goss MA, Lievano F, Siminack M, et al. No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy: 5 year pregnancy registry data (abstract no. SS 8-3). In: EUROGIN 2012: human papillomavirus, cervical and other human diseases. Prague; 8–11 Jun 2012.

  50. Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012;166(12):1140–8.

    Article  PubMed  Google Scholar 

  51. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750–7.

    Article  CAS  PubMed  Google Scholar 

  52. Centers for Disease Control and Prevention. CDC Wonder online VAERS database. 2013. http://wonder.cdc.gov/vaers.html. Accessed 3 Nov 2014.

  53. World Health Organization. Human papilloma vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014; p. 43.

Download references

Acknowledgments

The manuscript was reviewed by: E.A. Joura, Department of Gynaecology and Obstetrics, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; M. Petras, Preventative Medicine, Charles University in Prague - 2nd Faculty of Medicine, Prague, Czech Republic.

Disclosure

This article was updated from Drugs 2014;74(11):1253-83 [4] by salaried employees of Adis/Springer. The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Gillian M. Keating & Paul L. McCormack

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keating, G.M., McCormack, P.L. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a guide to its use in the EU. Drugs Ther Perspect 31, 1–8 (2015). https://doi.org/10.1007/s40267-014-0177-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-014-0177-6

Keywords

Search

Navigation